Fig 1: BaF3 cell invasion in each group. (A) BaF3 cell invasion in each group. (B) Histogram of BaF3 cell invasion rate in each group. #P<0.05 vs. the blank group; *P<0.05 vs. the shCRLF2 + LY294002 group. NC, negative control; sh, short hairpin; CRLF2, cytokine receptor-like factor 2.
Fig 2: BaF3 cell sensitivity to chemotherapeutic agents. (A) BaF3 cell apoptosis in each group. (B) Histogram of the BaF3 cell apoptosis rate in each group. #P<0.05 vs. the blank group, *P<0.05 vs. the shCRLF2 + LY294002 group. NC, negative control; sh, short hairpin; CRLF2, cytokine receptor-like factor 2; FITC, fluorescein isothiocyanate; PI, propidium iodide.
Fig 3: CRLF2 expression and the prognosis of the patients. (A) Comparison of OS in patients with high CRLF2 expression and low CRLF2 expression. (B) Comparison of EFS in patients with high CRLF2 expression and low CRLF2 expression. OS, overall survival; EFS, event-free survival; CRLF2, cytokine receptor-like factor 2.
Fig 4: Analysis of CRLF2 expression in bone marrow through immunohistochemistry. (A) Immunohistochemical staining of bone marrow tissues from normal healthy children and children with B-cell acute lymphoblastic leukemia. (B) Histogram of the positive cell rate of CRLF2 in each group. *P<0.05 vs. the normal group; #P<0.05 vs. the low expression group. CRLF2, cytokine receptor-like factor 2.
Fig 5: BaF3 cell viability in each group. #P<0.05 vs. the respective blank group; *P<0.05 vs. respective shCRLF2 + LY294002 group. OD, optical density; NC, negative control; sh, short hairpin; CRLF2, cytokine receptor-like factor 2.
Supplier Page from Abcam for Anti-CRLF2 antibody